TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00102336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
Study: NCT00847249
Drug: AZD9164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
Study: NCT02660970
Drug: Iberogast
Normalized name: Iberogast Softgels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will have to take Iberogast drops
Study: NCT04502901
Drug: KX0826
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational AR antagonist
Study: NCT00847249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single-dose.
Study: NCT03128359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04553458
Drug: Percutaneous ethanol injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection of HCC
Study: NCT04553458
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment
Study: NCT00915239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo once daily for 28 days
Study: NCT00741455
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/m2/d IV on days -3 and -2
Study: NCT00741455
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
Study: NCT00098319
Drug: Folic acid (0.4mg vs. 4.0mg)
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03014375
Drug: BIA-5-453
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
Study: NCT01968915
Drug: LCL161
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
Study: NCT01914900
Drug: docetaxel, cisplatin, 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03078322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT03284177
Drug: Calcium (13C)Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
Study: NCT03299322
Drug: Jia Wei Yang He granule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Made from 1/20 doses which has certain taste, but no therapeutic effect
Study: NCT00003834
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003834
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03284177
Drug: Gastric acid inhibitors
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
Study: NCT00242710
Drug: CE 0.45 mg/MPA 1.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Study: NCT02763059
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
Study: NCT02763059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group receives 1 hour before surgery placebo.
Study: NCT02763059
Drug: Acetaminophen 1000 mg
Normalized name: acetaminophen 1000 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
Study: NCT00120926
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01018030
Drug: FFNS 110 mcg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
Study: NCT01018030
Drug: FFNS 110 mcg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Nasal Spray (AM) and Active Nasal Spray (PM)
Study: NCT01018030
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
Study: NCT03862586
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00890734
Drug: CYT003-QbG10
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT00890734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT00648336
Drug: Mercaptopurine 50 mg
Normalized name: mercaptopurine 50 MG
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg, single dose fasting
Study: NCT00648336
Drug: Purinethol® Tablets 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg, single dose fasting
Study: NCT02460094
Drug: BIIB092
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Descriptions for dosing information.
Study: NCT02460094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
Study: NCT00373373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Placebo
Study: NCT01792310
Drug: LAM561
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances.
Study: NCT03401372
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doxycycline 100mg twice daily
Study: NCT03401372
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
Study: NCT01336543
Drug: Chemotherapy following concurrent Chemoradiotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles
Study: NCT00296036
Drug: urea/lactic acid-based topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically
Study: NCT05414669
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was given orally for a total of 3 days, beginning a day before ESWL.
Study: NCT00875966
Drug: Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
Study: NCT02021864
Drug: prenatal multivitamin
Normalized name: Prenatal Multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
Study: NCT00544154
Drug: CDP870
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03830463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT01836029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00362440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01070940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution IV priming dose + IV infusion for 1 hour
Study: NCT00925977
Drug: Insulin NPH + Insulin Apidra: Active Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin NPH + Insulin Apidra: Active Comparator
Study: NCT01526499
Drug: Docetaxel and Cyclophosphamide (TC)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
Study: NCT01651767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=suspension, route=oral.
Study: NCT02466906
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
Study: NCT01066611
Drug: CAL-263
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL-263 10 mg or placebo once daily for 7 days
Study: NCT01066611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL-263 10 mg or placebo once daily for 7 days
Study: NCT04797923
Drug: 1. Treatment: IP chemotherapy + Systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
Study: NCT00429091
Drug: ABT-894
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
Study: NCT00082628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to serostim® as subcutaneous injection.
Study: NCT00082628
Drug: Serostim® 4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
Study: NCT00082628
Drug: Serostim® 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serostim® 2 mg as subcutaneous injection on alternate days.
Study: NCT00429091
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take BID for up to four weeks
Study: NCT01045460
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 2.5 g/m\^2.
Study: NCT00011986
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03338816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (normal saline \[0.9% NaCl\]) by SC
Study: NCT00988858
Drug: LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
Study: NCT03773068
Drug: [13C715N]-BAY 181708 stable isotope label (SIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
Study: NCT00004236
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00252421
Drug: Placebo ointment daily for 24 month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied daily for 24 mth
Study: NCT00189098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03446872
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: an active metabolite of folic acid
Study: NCT01600885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
Study: NCT03101930
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
Study: NCT01021553
Drug: GSK557296
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg GSK557296
Study: NCT01021553
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02180464
Drug: LAS41004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396344
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous stress dose of hydrocortisone
Study: NCT00396344
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous pharmacologic hydrocortisone
Study: NCT02319200
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets per day for 36 months
Study: NCT02481154
Drug: AG881
Normalized name: Agenebrutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Study: NCT01087229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesitherapy is performed with a mask by which patient inhales a placebo.
Study: NCT02073227
Drug: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study: NCT00456053
Drug: FG2216
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01306786
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d
Study: NCT01306786
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
Study: NCT02268149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00491751
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid 500 mg/day
Study: NCT00491751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02455596
Drug: Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
Study: NCT01888744
Drug: hP-hMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00785915
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration and once daily for 5 days
Study: NCT00785915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration and once daily for 5 days
Study: NCT02662894
Drug: Valsartan 160mg + Rosuvastatin 20mg
Normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet, oral, a day
Study: NCT02662894
Drug: Valsartan 320mg + Rosuvastatin 20mg
Normalized name: valsartan 320 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet, oral, a day
Study: NCT02538744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02662894
Drug: Diovan® 160mg + Crestor® 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Study: NCT02662894
Drug: Diovan® 320mg + Crestor® 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Study: NCT00472108
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01387217
Drug: GSK2018682
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2018682
Study: NCT01387217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT00642356
Drug: Carbidopa/levodopa/entacapone
Normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
Study: NCT00642356
Drug: Immediate release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
Study: NCT01472640
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 U sc QOD
Study: NCT00686504
Drug: radioligand [11C] AZ12713580
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of iv administered 4 times per subject (3 times together with AZD2066)
Study: NCT03169894
Drug: MDGN-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
Study: NCT02160951
Drug: LGH447
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGH447, QD
Study: NCT00972439
Drug: Oral Contraceptive: Ortho-Novum® 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02076659
Drug: F8IL10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Study: NCT02076659
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Study: NCT03671252
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
Study: NCT03671252
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
Study: NCT03705156
Drug: ZL-2306(nirapairb)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is 300 mg or 200 mg based on patient's body weight.
Study: NCT03705156
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
Study: NCT01742663
Drug: Solaraze® (diclofenac sodium) Gel 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
Study: NCT00150241
Drug: CP-526,555 (varenicline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01657214
Drug: SAR125844
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Concentrate for solution~Route of administration: intravenous
Study: NCT02094807
Drug: opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
Study: NCT01896349
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
Study: NCT02332512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01550549
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read